Osteogenic potential of mesenchymal stromal cells contributes to primary myelofibrosis

Cancer Research

Volumn 75, Issue 22, 2015, Pages 4753-4765

  Martinaud, Christophe ^a,b,c,d   Desterke, Christophe ^a,b   Konopacki, Johanna ^c   Pieri, Lisa ^e   Torossian, Frédéric ^a,b   Golub, Rachel ^f,g,h   Schmutz, Sandrine ^f   Anginot, Adrienne ^a,b   Guerton, Bernadette ^a,b   Rochet, Nathalie ⁱ   Albanese, Patricia ^j   Henault, Emilie ^j   Pierre Louis, Olivier ^k   Souraud, Jean Baptiste ^c   De Revel, Thierry ^c   Dupriez, Brigitte ^d   Ianotto, Jean Christophe ^l   Bourgeade, Marie Françoise ^m,n   Vannucchi, Alessandro M ^e   Lataillade, Jean Jacques ^a,o,p   Le Bousse Kerdilès, Marie Caroline ^a,b,d   more..

^a Paris Sud 11 University   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c Percy Military Teaching Hospital   (France)

^d French Intergroup on Myeloproliferative Neoplasms ^*  (France)

^e CAREGGI UNIVERSITY HOSPITAL   (Italy)

^f INSTITUT PASTEUR   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h INSTITUT PASTEUR   (France)

ⁱ UNIVERSITÉ CÔTE D'AZUR   (France)

^j EAC 7149 ^*  (France)

^k Etablissement Français du Sang   (Martinique)

^l BREST UNIVERSITY HOSPITAL   (France)

^m INSERM   (France)

ⁿ HÔPITAL PAUL BROUSSE   (France)

^o Research and Cell Therapy Department   (France)

^p Army Biomedical Research Institute   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; CHONDROITIN SULFATE; HEPARAN SULFATE; SMAD2 PROTEIN; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; MALE; MESENCHYMAL STROMA CELL; MIDDLE AGED; MOUSE; MYELOID METAPLASIA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; VERY ELDERLY; ANIMAL; CELL CULTURE; HETEROTOPIC OSSIFICATION; NUDE MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; POLYMERASE CHAIN REACTION; XENOGRAFT;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CELL DIFFERENTIATION; CELLS, CULTURED; FEMALE; HETEROGRAFTS; HUMANS; MALE; MESENCHYMAL STROMAL CELLS; MICE; MICE, NUDE; MIDDLE AGED; OSSIFICATION, HETEROTOPIC; POLYMERASE CHAIN REACTION; PRIMARY MYELOFIBROSIS;

EID: 84948414542     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-3696     Document Type: Article

References (48)

1. Le Bousse-Kerdiles MC. Primary myelofibrosis and the "bad seeds in bad soil" concept. Fibrogenesis Tissue Repair 2012;5:S20.
2. Lataillade JJ, Pierre-Louis O, Hasselbalch HC, Uzan G, Jasmin C, Martyre MC, et al. Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence. Blood 2008;112:3026-35.
3. Brouty-Boye D, Briard D, Azzarone B, Le Bousse-Kerdiles MC, Clay D, Pottin-Clemenceau C, et al. Effects of human fibroblasts from myelometaplasic and non-myelometaplasic hematopoietic tissues on CD34+ stem cells. Int J Cancer 2001;92:484-8.
4. Walkley CR, Olsen GH, Dworkin S, Fabb SA, Swann J, McArthur GA, et al. A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency. Cell 2007;129:1097-110.
5. Tripodo C, Sangaletti S, Guarnotta C, Piccaluga PP, Cacciatore M, Giuliano M, et al. Stromal SPARC contributes to the detrimental fibrotic changes associated with myeloproliferation while its deficiency favors myeloid cell expansion. Blood 2012:1-39.
6. Frenette PS, Pinho S, Lucas D, Scheiermann C. Mesenchymal stem cell: keystone of the hematopoietic stem cell niche and a stepping-stone for regenerative medicine. Annu Rev Immunol 2013;31:285-316.
7. Tripodo C, Di Bernardo A, Ternullo MP, Guarnotta C, Porcasi R, Ingrao S, et al. CD146(+) bone marrow osteoprogenitors increase in the advanced stages of primary myelofibrosis. Haematologica 2009;94:127-30.
8. Avanzini MA, Bernardo ME, Novara F, Mantelli M, Poletto V, Villani L, et al. Functional and genetic aberrations of in vitro-cultured marrow-derived mesenchymal stromal cells of patients with classical Philadelphia-negative myeloproliferative neoplasms. Leukemia 2014;28:1742-5.
9. Tefferi A, Thiele J, Vardiman JW. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer 2009;115:3842-7.
10. Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013;369:2379-90.
11. Lataillade J-J, Clay D, Bourin P, Hérodin F, Dupuy C, Jasmin C, et al. Stromal cell-derived factor 1 regulates primitive hematopoiesis by suppressing apoptosis and by promoting G(0)/G(1) transition in CD34(+) cells: evidence for an autocrine/paracrine mechanism. Blood 2002;99: 1117-29.
12. Huynh MB, Morin C, Carpentier G, Garcia-Filipe S, Talhas-Perret S, Barbier-Chassefiere V, et al. Age-related changes in rat myocardium involve altered capacities of glycosaminoglycans to potentiate growth factor functions and heparan sulfate-altered sulfation. J Biol Chem 2012;287:11363-73.
13. Destouches D, Huet E, Sader M, Frechault S, Carpentier G, Ayoul F, et al. Multivalent pseudopeptides targeting cell surface nucleoproteins inhibit cancer cell invasion through tissue inhibitor of metalloproteinases 3 (TIMP-3) release. J Biol Chem 2012;287:43685-93.
14. Barbosa I, Garcia S, Barbier-Chassefiere V, Caruelle JP, Martelly I, Papy-Garcia D. Improved and simple micro assay for sulfated glycosaminoglycans quantification in biological extracts and its use in skin and muscle tissue studies. Glycobiology 2003;13:647-53.
15. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545-50.
16. Bouvet-Gerbettaz S, Boukhechba F, Balaguer E, Schmid-Grendelmeier P, Michiels C, Smimeca JC, et al. Adaptative immune response inhibits ectopic mature bone formation induced by BMSCs/BCP/plasma composite in immune competent mice. Tissue Eng Part A 2014;20:2950-62.
17. Doucet C, Ernou I, Zhang Y, Llense JR, Begot L, Holy X, et al. Platelet lysates promote mesenchymal stem cell expansion: a safety substitute for animal serum in cell-based therapy applications. J Cell Physiol 2005; 205:228-36.
18. Cao JJ, Singleton PA, Majumdar S, Boudignon B, Burghardt A, Kurimoto P, et al. Hyaluronan increases RANKL expression in bone marrow stromal cells through CD44. J Bone Miner Res 2004;20:30-40.
19. Inman GJ, Nicolas FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, et al. SB-431542 is a potent and specific inhibitor of transforming growth factorbeta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 2002;62:65-74.
20. Boergermann JH, Kopf J, Yu PB, Knaus P. Dorsomorphin and LDN-193189 inhibit BMP-mediated Smad, p38 and Akt signalling in C2C12 cells. Int J Biochem Cell Biol 2010;42:1802-7.
21. Noirez P, Torres S, Cebrian J, Agbulut O, Peltzer J, Butler-Browne G, et al. TGF-beta1 favors the development of fast type identity during soleus muscle regeneration. J Muscle Res Cell Motil 2006;27:1-8.
22. Delorme B, Ringe J, Pontikoglou C, Gaillard J, Langonn A, Senseb L, et al. Specific lineage-priming of bone marrow mesenchymal stem cells provides the molecular framework for their plasticity. Stem Cells 2009; 27:1142-51.
23. Javed A, Chen H, Ghori FY. Genetic and Transcriptional Control of Bone Formation. Oral Maxillofac Surg Clin North Am 2010;22: 283-93.
24. Laiho M, Saksela O, Keski-Oja J. Transforming growth factor-beta induction of type-1 plasminogen activator inhibitor. Pericellular deposition and sensitivity to exogenous urokinase. J Biol Chem 1987;262: 17467-74.
25. Walenda G, Abnaof K, Joussen S, Meurer S, Smeets H, Rath Br, et al. TGFbeta1 does not induce senescence of multipotent mesenchymal stromal cells and has similar effects in early and late passages. PLoS ONE 2013;8: e77656.
26. Hasselbalch HC. Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development? Leuk Res 2013;37: 214-20.
27. Zhao Z-G, Liang Y, Li K, Li W-M, Li Q-B, Chen Z-C, et al. Phenotypic and functional comparison of mesenchymal stem cells derived from the bone marrow of normal adults and patients with hematologic malignant diseases. Stem Cells Dev 2007;16:637-48.
28. Andrieux J, Roche-Lestienne C, Geffroy S, Desterke C, Grardel N, Plantier I, et al. Bone morphogenetic protein antagonist gene NOG is involved in myeloproliferative disease associated with myelofibrosis. Cancer Genet Cytogenet 2007;178:11-6.
29. Manton KJ, Leong DF, Cool SM, Nurcombe V. Disruption of heparan and chondroitin sulfate signaling enhances mesenchymal stem cell-derived osteogenic differentiation via bone morphogenetic protein signaling pathways. Stem Cells 2007;25:2845-54.
30. Miraoui H, Marie PJ. Pivotal role of Twist in skeletal biology and pathology. Gene 2010;468:1-7.
31. Koch FP, Weinbach C, Hustert E, Al-Nawas B, Wagner W. GDF-5 and BMP-2 regulate bone cell differentiation by gene expression of MSX1, MSX2, Dlx5, and Runx2 and influence OCN gene expression in vitro. Int J Periodontics Restorative Dent 2012;32:285-93.
32. Harrison JS, Corcoran KE, Joshi D, Sophacleus C, Rameshwar P. Peripheral monocytes and CD4+ cells are potential sources for increased circulating levels of TGF-beta and substance P in autoimmune myelofibrosis. Am J Hematol 2006;81:51-8.
33. Coombe DR. Biological implications of glycosaminoglycan interactions with haemopoietic cytokines. Immunol Cell Biol 2008;86: 598-607.
34. Mathews S, Mathew SA, Gupta PK, Bhonde R, Totey S. Glycosaminoglycans enhance osteoblast differentiation of bone marrow derived human mesenchymal stem cells. J Tissue Eng Regen Med 2014;8:143-52.
35. Erlebacher A, Derynck R. Increased expression of TGF-beta 2 in osteoblasts results in an osteoporosis-like phenotype. J Cell Biol 1996; 132:195-210.
36. Takada T, Katagiri T, Ifuku M, Morimura N, Kobayashi M, Hasegawa K, et al. Sulfated polysaccharides enhance the biological activities of bone morphogenetic proteins. J Biol Chem 2003;278:43229-35.
37. Kanzaki S, Takahashi T, Kanno T, Ariyoshi W, Shinmyouzu K, Tujisawa T, et al. Heparin inhibits BMP-2 osteogenic bioactivity by binding to both BMP-2 and BMP receptor. J Cell Physiol 2008;216:844-50.
38. Freytag J, Wilkins-Port CE, Higgins CE, Higgins SP, Samarakoon R, Higgins PJ. PAI-1 mediates the TGF-beta1+EGF-induced "scatter" response in transformed human keratinocytes. J Invest Dermatol 2010;130:2179-90.
39. Wipff P-J, Hinz B. Integrins and the activation of latent transforming growth factor beta1 - an intimate relationship. Eur J Cell Biol 2008;87:601-15.
40. Ell B, Kang Y. MicroRNAs as regulators of bone homeostasis and bone metastasis. Bonekey Rep 2014;3:549.
41. Rippo MR, Olivieri F, Monsurro V, Prattichizzo F, Albertini MC, Procopio AD. MitomiRs in human inflamm-aging: a hypothesis involvingmiR-181a, miR-34a and miR-146a. Exp Gerontol 2014;56:154-63.
42. Hasselbalch HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood 2012;119:3219-25.
43. Anderson JE, Sale G, Appelbaum FR, Chauncey TR, Storb R. Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis. Br J Haematol 1997;98:1010-6.
44. Thiele J, Kvasnicka HM, Dietrich H, Stein G, Hann M, Kaminski A, et al. Dynamics of bone marrow changes in patients with chronic idiopathic myelofibrosis following allogeneic stem cell transplantation. Histol Histopathol 2005;20:879-89.
45. Deeg HJ, Gooley TA, Flowers ME, Sale GE, Slattery JT, Anasetti C, et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 2003;102:3912-8.
46. Kroger N, Kvasnicka M, Thiele J. Replacement of hematopoietic system by allogeneic stem cell transplantation in myelofibrosis patients induces rapid regression of bone marrow fibrosis. Fibrogenesis Tissue Repair 2012;5:S25.
47. Cervantes F, Rovira M, Urbano-Ispizua A, Rozman M, Carreras E, Montserrat E. Complete remission of idiopathic myelofibrosis following donor lymphocyte infusion after failure of allogeneic transplantation: demonstration of a graft-versus-myelofibrosis effect. Bone Marrow Transplant 2000;26:697-9.
48. Laperrousaz B, Jeanpierre S, Sagorny K, Voeltzel T, Ramas S, Kaniewski B, et al. Primitive CML cell expansion relies on abnormal levels of BMPs provided by the niche and on BMPRIb overexpression. Blood 2013;122: 3767-77.